Table 1.
Baseline characteristics of the study population.
| Unmatching | Matching * | ||||
|---|---|---|---|---|---|
| Dox-ICI Cohort (n = 22) | Dox Cohort (n = 73) | p Value | Dox Cohort (n = 22) | p Value † | |
| Age | 51 ± 14 | 53 ± 14 | 0.587 | 51 ± 14 | 0.985 |
| Male, n (%) | 14 (48.3) | 27 (39.1) | 0.402 | 14 (48.3) | 1.000 |
| Cardiovascular risk factors | |||||
| Hypertension, n (%) | 5 (17.2) | 16 (22.2) | 0.598 | 6 (20.7) | 0.783 |
| Diabetes, n (%) | 3 (10.3) | 7 (9.5) | 0.976 | 4 (13.8) | 0.687 |
| Dyslipidemia, n (%) | 2 (6.9) | 1 (1.3) | 0.153 | 0 (0) | 0.150 |
| Atrial fibrillation, n (%) | 1 (3.4) | 5 (6.8) | 0.474 | 3 (10.3) | 0.300 |
| Coronary artery disease, n (%) | 1 (3.4) | 1 (1.3) | 0.523 | 0 (0) | 0.313 |
| Chronic kidney disease, n (%) | 0 (0) | 12 (16.4) | 0.017 | 5 (17.2) | 0.019 |
| Baseline physical findings | 117 ± 11 | 113 ± 19 | 0.409 | 113 ± 19 | 0.409 |
| Systolic blood pressure, mmHg | 117 ± 11 | 113 ± 19 | 0.409 | 114 ± 19 | 0.395 |
| Diastolic blood pressure, mmHg | 71 ± 10 | 70 ± 17 | 0.841 | 69 ± 21 | 0.705 |
| BSA, kg/m2 | 1.67 ± 0.17 | 1.63 ± 0.22 | 0.472 | 1.63 ± 0.20 | 0.448 |
| Medication | |||||
| Beta blocker, n (%) | 1 (4.5) | 2 (2.7) | 0.667 | 1 (4.5) | 0.879 |
| ACE-I or ARB, n (%) | 3 (13.6) | 10 (13.6) | 0.469 | 5 (22.7) | 0.447 |
| Statin, n (%) | 5 (22.7) | 12 (16.4) | 0.145 | 6 (27.2) | 0.256 |
| Adriamycin cumulative dose, mg/m2 | 395 ± 49 | 400 ± 56 | 0.820 | 398 ± 55 | 0.954 |
ACE-I, angiotensin-converting enzyme inhibitor; ARB, angiotensin receptor blocker; BSA, body surface area. * Matching for age, sex and adriamycin cumulative dose; † p for Dox-ICI group and matching Dox group.